Abstract
Introduction
Acute coronary syndrome (ACS) can be defined as any group of clinical symptoms consistent with acute myocardial ischemia. This may include unstable angina (UA), non-ST-segment elevation and ST-segment elevation myocardial infarction. Management of acute coronary syndrome may consist of antiplatelet therapy, angiography and further interventions depending upon the findings of angiography 1 . Antiplatelet therapy is an essential part of management of patients with acute coronary syndrome and may consist of aspirin (irreversibly inhibiting cyclooxygenase 1), clopidogrel (P2Y12 adenosine diphosphate receptor blocker), newer P2Y12 ADP Inhibitors (Prasugrel & Ticagrelor) and GP IIb/IIIa Inhibitors. Choosing antiplatelet therapy for a particular patient is a crucial decision for treating cardiologist keeping in mind patient profile, presence of co-morbidities such as diabetes, hypertension and chronic obstructive pulmonary disease 2 .
Its common for patients who have been diagnosed with acute coronary syndrome to have other comorbidities such as diabetes, hypertension and chronic obstructive pulmonary disease (COPD) 3 .
Moreover, patients with COPD are at an increased risk of acute coronary syndrome because of risk factors which are common for COPD as well as acute coronary syndrome such as smoking, increasing age and obesity 4 . Shared risk factors
are not the only cause of increased risk of acute coronary syndrome in patients with COPD but also there are studies which have showed that the COPD is an independent risk factor for adverse cardiac events such as acute coronary syndrome, unstable angina and even sudden cardiac arrests have been reported in patients with COPD. Moreover, even in properly treated patients with acute coronary syndrome presence of COPD is found to be an independent risk factor for recurrent ischemic events and mortality 5 .
Given the high chances of COPD in patients with acute coronary syndrome effect of therapy on lung function becomes one of the important considerations while selecting antiplatelet therapy 6 Since there were conflicting reports about suitability of Ticagrelor in patients with acute coronary syndrome and concomitant chronic obstructive airway disease and incidence of dyspnea we decided to undertake this comparative study of pulmonary function tests in patients with acute coronary syndrome treated by Ticagrelor and Clopidogrel.
Materials and Methods
This was a prospective comparative study in which a total 120 patients with acute coronary syndrome were enrolled depending upon a predefined inclusion and exclusion criteria. The analysis of age groups of the patients showed that in both the groups most of the patients were between the age group of 61-65 years (51.67% (Group A) and 58.33% (Group B)) followed by 66-70 years (20% (Group A) and 21.67% (Group B)) and 55-60 years (18.33% (Group A) and 15.00% (Group B)). Only 9 (7.5%) patients were below the age of 55 years. The mean age of the patients in group A and group B was found to be 61.56 +/-3.98 and 62.41 +/-3.40 respectively. Mean age of the patients in both the groups was found to be comparable and there was no statistically significant difference in mean ages of both the groups (P>0.05). The analysis of body mass index of the studied cases showed that in group A majority of the patients (55%) were overweight (BMI=\> 25 but < 30) whereas 15 (25%) were obese (BMI =/> 30). 12 (30%) patients were having normal BMI (< 25). IN group B normal BMI, overweight and obesity was seen in 9 (15%), 12 (20%) and 39 (65%) patients respectively.
Figure 1: BMI of the studied cases
The analysis of patients on the basis of presence of co-morbid conditions showed that in group A out of 60 patients 40 (66.67%) patients had hypertension. Other co-morbid conditions included dyslipidemia 36 (60.00%), diabetes mellitus 22(36.67%), chronic renal diseases 5(8.33%) and peripheral artery disease 3(5.00%). In group B hypertension, dyslipidemia, diabetes mellitus, chronic renal disease and peripheral artery disease was present in 35 (58.33%), 32 (53.33%), 24 (40.00%), 4 (6.67%) and 2 (3.33%) patients respectively. Patients either received ticagrelor (90 mg twice daily) (Group A) or clopidogrel (75 mg once daily) (Group B). Before beginning of therapy pulmonary function tests were done and after 30 days' continuous therapy pulmonary function tests were repeated. Comparison of pulmonary functions in both the groups was done. The analysis of forced expiratory volume in 1 second (FEV1) was done in both the cases. The mean FEV1 in group A and B was found to be 2.69 +/-0.68 and 2.63 +/-0.56 respectively. Mean FEV1 values were found to be comparable in both the groups and there was no statistically significant difference in FEV1 of both the groups. The analysis of FEV1/FVC ratio showed that it was 71 +/-5.6 % and72 +/-4.8% in group A and group B respectively. The FEV1/FVC ratio were found to be comparable in both the groups and there was no statistically significant difference (P=0.29) FEF25-75 % of the patients in both the groups was analyzed. It was found that the mean FEF25-75 % in group A and group B was 75.26 +/-3.92 and group was 75.35 +/-5.33 respectively. The mean FEF25-75 % of both the groups were found to be comparable and there was no statistically significant difference in the mean FEF25-75 % of both the groups (P=0.91). 
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Figure 3: FEF25-75 % in studied cases
The analysis of SPo2 % of the patients in both the groups showed that mean SPO2 in group A was 97.49 +/-0.75 whereas mean SPO2 in group B was found to be 97.27 +/-0.86. The mean SPO2 levels in group A and Group B were found to be comparable and there was no statistically significant difference in mean SPO2 of both the groups (P=0.13).
Figure 4: SPO2 % in studied cases

Discussion
This was a prospective comparative study of pulmonary function tests in patients with acute coronary syndrome treated by Ticagrelor (Group A) and Clopidogrel (Group B). In our study there were 80 (66.67%) males and 40 (33.33%) females with a M:F ratio of 1:0.5. The male preponderance in patients of coronary artery disease is wellknown. Jamee A et al in a cross-sectional study based on 155 cardiac patients found that Myocardial infarction in male compared with female was 2 times higher 11 . Estrogen in females is found to have a cardioprotective role. It further delays the manifestation of atherosclerotic disease in women. Similarly, Folsam AR examined a population-based sample (n = 13,446 free of baseline CHD). The purpose of the study was to determine the association of coronary heart On the basis of these findings the authors concluded that Ticagrelor in ACS patients is not associated with any detectable detrimental effect on pulmonary function compared to clopidogrel. Similar findings were also reported by the studies conducted by Butler K et al 19 and Andell P et al 20 .
Conclusion
Ticagrelor is associated with a considerable reduction in cardiovascular death, myocardial infarction and stroke in patients with coronary artery diseases. PLATO trial reported that there was an increased incidence of dyspnea in patients who had been given ticagrelor. These findings have discouraged use of ticagrelor in CAD patients. Our study found that ticagrelor does not affect pulmonary functions and hence can be considered a better option as compared to clopidogrel in patients with CAD.
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